# Primary Endpoint: Progression-Free Survival (28.3 Month Follow up)

## Superior Progression-Free Survival with acalabrutinib-O compared to O-Clb

![](https://ref--repo--owner.hlx.page/media_1c21561250d5da5c8cc7420cec38cd4ef8c0e8780.png#width=1\&height=1)
